热门资讯> 正文
Genmat表示，2024年DARZAFLEX净销售额总计116.7亿美元
2025-01-22 19:36
- Genmab A/S (GMAB) Wednesday reported that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous product, as reported by J&J were $11,670 million in 2024.
- Net trade sales were $6,588 million in the U.S. and $5,082 million in the rest of the world.
- Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J (JNJ) to develop, manufacture and commercialize daratumumab.
- Source: Press Release
More on Genmab
- Genmab A/S: Circling Back On This Complicated Story
- Genmab Is Too Attractive To Ignore
- Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript
- Seeking Alpha’s Quant Rating on Genmab
- Historical earnings data for Genmab
推荐文章
黄仁勋年内三度访华！H20重返中国市场，释放了什么信号？
华盛早报丨TACO交易再现！特朗普闪电改口“解雇鲍威尔”；美国众议院加密货币立法进程受阻
财报前瞻 | 特斯拉Q2营收料下滑10%！股价销量双杀下，马斯克能否逆转局势？
美股机会日报 | 低于市场预期！美国6月PPI同比增长2.3%；特斯拉官宣Model Y L
华盛早报丨事关中美关税！美财长最新放风；“加密周”突发！多项加密货币法案遭众议院否决
7月财报预告丨迎关税考验！特斯拉、台积电放榜在即，美股能否守住涨势？
美股机会日报 | 6月CPI符合预期！英伟达盘前涨超4%，今夜有望再创新高
美股机会日报 | 史上首次！比特币升破12万美元；马斯克：特斯拉年底会有“史诗级震撼”的演示
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
